# REJOICE-Ovarian01 (NCT06161025)

> A Study of Raludotatug Deruxtecan (R-DXd) in Subjects With Platinum-resistant, High-grade Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT06161025
- Phase: PHASE2, PHASE3
- Status: RECRUITING
- Sponsor: Daiichi Sankyo
- Conditions: Solid Cancer
- Interventions: R-DXd; Paclitaxel; Topotecan; PLD
- Enrollment: 860
- Primary outcome: Objective Response Rate (ORR) Based on Blinded Independent Central Review (BICR) Assessment (Part A)
- Primary outcome: Progression-free Survival (PFS) Based on BICR Assessment (Part B)

## Indexed commentary on REJOICE-Ovarian01 so far

Podcasts, YouTube videos and X posts we have indexed that name the trial. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.

- Podcasts: 8
- YouTube: 6
- X threads: 2

## Order

Standard, $1,250, price fixed at order: https://www.erudio.com/contact?report=rejoice-ovarian01-nct06161025

## Free preview

POST https://www.erudio.com/api/trial-requests with {"nct_id": "NCT06161025", "email": "<work email>"}; the inbox owner confirms by the emailed link.